Shots:

• Spark to get exclusive- WW license to develop- manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program
• The companies will work together and will leverage their knowledge to address unmet needs for people living with drug-resistant focal epilepsy
• CG01 is an investigational gene therapy that aims to treat drug resistant focal epilepsy

  | Ref: Spark Therapeutics | Image: Ophthamology Innovation Summit